Geron Shares Plunge Following Disappointing Quarterly Results

Geron Corporation witnessed a significant sell-off in its stock price on Friday, with shares declining by more than 9%. This sharp drop reflects widespread investor disappointment triggered by the company’s latest quarterly earnings report, which revealed a substantial revenue shortfall. While the biotech firm managed to meet analyst expectations for its loss per share, its top-line performance fell well below market forecasts.

In a major strategic move at the end of October, Geron implemented sweeping changes to its leadership team. The company’s Chief Operating Officer and Chief Commercial Officer both departed from their roles. Ahmed ElNawawi has stepped into the position of new Commercial Chief, tasked with the critical mission Read more...